Skip to main content
. Author manuscript; available in PMC: 2017 Sep 19.
Published in final edited form as: Xenotransplantation. 2013 Oct 29;21(1):35–45. doi: 10.1111/xen.12066

Fig. 2.

Fig. 2

B lymphocytes and non-Gal antibody titers: (A) Percentage of CD20+ B lymphocytes present in the peripheral blood throughout the graft survival period, (B) non-Gal IgM (a) and IgG (b) antibodies before and after transplantation, and (C) comparison of average mean fluorescence intensity of non-Gal IgM (a) and IgG (b) antibody in two treatment groups before transplantation, after transplantation up to day 60 and after discontinuing the antibody after day 60 until the graft rejection.